Why Nuwellis Shares Are Trading Higher Today
Portfolio Pulse from Nabaparna Bhattacharya
Nuwellis and DaVita have entered a supply and collaboration pact to pilot Aquadex ultrafiltration therapy for adult patients with congestive heart failure in select U.S. markets. The pilot program is expected to launch by Q3 2023 and extend through May 31, 2024. Nuwellis issued DaVita a warrant for approximately 1.3 million shares of Nuwellis common stock.
June 20, 2023 | 3:12 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
DaVita has entered a collaboration with Nuwellis to pilot Aquadex ultrafiltration therapy for adult patients with congestive heart failure.
The collaboration with Nuwellis will allow DaVita to expand its care offerings for heart failure patients. Additionally, DaVita received a warrant for approximately 1.3 million shares of Nuwellis common stock, which could provide a potential financial benefit for the company, positively impacting its stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100
POSITIVE IMPACT
Nuwellis shares are trading higher after entering a collaboration with DaVita to pilot Aquadex ultrafiltration therapy for heart failure patients.
The collaboration with DaVita is expected to expand access to ultrafiltration therapy for millions of heart failure patients in the U.S. and reduce related healthcare costs. This partnership could enable accelerated commercial expansion of the therapy, positively impacting Nuwellis' stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100